NDAINJECTIONINJECTABLE
Approved
Dec 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Wyamine Sulfate (mephentermine sulfate) is an injectable sympathomimetic amine approved in 1951 for acute hypotensive episodes. It acts as an adrenergic stimulant to raise blood pressure through direct and indirect mechanisms. This product represents a legacy injectable vasopressor used in acute care and anesthesia settings.
LOE Approaching
Limited commercial opportunity exists as this legacy injectable approaches loss of exclusivity with minimal modern marketing infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Opportunities on Wyamine Sulfate are severely limited, with zero linked job openings reflecting its legacy status and declining commercial profile. Professionals joining this product face a career assignment focused on defensive management rather than growth and innovation.
Brand ManagerField Sales Representative
Worked on WYAMINE SULFATE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.